Organic chemistry (C07)

C   Chemistry; metallurgy(318327)
C07            Organic chemistry(61593)
C07M - (20)
ethod of producing pentafluoroiodoethane // 2642789
FIELD: chemistry.SUBSTANCE: invention relates to the method of producing pentafluoroiodoethane from perfluoro-propene, which includes the interaction of CF3CF=CF2 with the iodine source, such as iodine-halide I-I, I-Br, I-Cl in the presence of inorganic fluoride, or perfluoro-isopropyl-iodide, and sodium methylate in the polar aprotic solvent with the formation of 1,1,1,2,3,3-hexafluoro-2-iodine-3-methoxy-propane, its subsequent demethylation by boiling with pentachloride antimony with obtaining 2,3,3,3-tetrafluoro-2-iodopropionyl fluoride, and decarbonylation of the latter under the action of pentafluoride antimony on heating, which gives pentafluoroiodetane.EFFECT: use of available non-explosive raw materials.4 cl, 5 ex

ethod and system for lignin processing // 2642787
FIELD: chemistry.SUBSTANCE: method of separating lignin from lignin-containing medium, such as liquid made in the method of processing biomass, for example, from a black alkaline solution produced in the enterprise of recycling of pulp, and processing the separated lignin, includes: the precipitation of lignin from lignin-containing liquid medium, followed by exposure of lignin hydrothermal carbonization in the wet state and the removal of carbonaceous material derived from lignin as a result of the carbonization after the implementation of the hydrothermal carbonization, the method further includes: the regulation of the particle size of the carbonaceous material by bringing the pH value of lignin in the wet state before the hydrothermal carbonization to a value exceeding 7, preferably exceeding 8. The system, a carbon-containing product and the application of the product are also declared.EFFECT: obtaining a hydrocarbon product with a controlled particle size and increasing the profitability of the process.17 cl, 2 dwg

Fluorine-9-methyl-β-carbolines // 2642785
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the general formula (I) , where R1 is -F, and R2 is -H or -F, or R1 is -H, and R2 is -F; which can be used as a medicine for treatment of diseases and/or injuries of the inner ear.EFFECT: increased efficiency of compounds.10 cl, 30 dwg, 1 tbl, 9 ex
Forzicyaside sulfate and its derivatives, method for its production and its application // 2642784
FIELD: pharmacology.SUBSTANCE: invention relates to forzicyaside sulfate and its derivative represented by the following formula , wherein R is Na+, K+ or NH+, and a method for their preparation, as well as an antiviral drug based on them and its use.EFFECT: increased efficiency of agents.10 cl, 9 tbl, 2 dwg
New benzoazepine derivative and its medical application // 2642783
FIELD: pharmacology.SUBSTANCE: invention relates to a new benzoazepine derivative of formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a hydroxyl group, a lower alkoxy group or , where A is absent or a lower alkylene group which may be substituted by a lower alkyl group; R6 represents a hydrogen atom or a lower alkyl group; R7 represents a hydrogen atom, a hydroxyl group, a five-membered aromatic heterocyclic group containing 3 heteroatoms selected from nitrogen and oxygen which may be substituted by a lower alkyl group, a five-membered non-aromatic heterocyclic group containing one nitrogen atom which may be substituted by an oxo group or a carbamoyl group , which may be substituted by a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 is a lower alkyl group which may be substituted by 1 to 3 fluorine atoms or a halogen atom; R4 represents a lower alkoxy group which may be substituted by 1 to 3 halogen atoms, a five-membered aromatic monocyclic heterocyclic group or a five-membered non-aromatic monocyclic heterocyclic group (provided that each of these heterocyclic groups contains one nitrogen atom, two nitrogen atoms or one nitrogen atom and one oxygen atom in the ring, and may contain a lower alkyl group); and R5 represents a hydrogen atom, a lower alkyl group or a halogen atom. The invention also relates to a pharmaceutical composition based on a compound of the formula and intermediates of the formulas and .EFFECT: new benzoazepine derivatives having V2 receptor agonist activity are obtained.14 cl, 12 tbl, 128 ex
Comt inhibitors // 2642779
FIELD: pharmacology.SUBSTANCE: invention relates to new compounds of the formula (I) and their pharmaceutically acceptable salts which have the properties of a catechol-O-methyltransferase (COMT) inhibitor. In the compound of the formula (I) , where R1 is hydrogen, methyl, Br, F or Cl; R2 is hydrogen, lower alkyl, Br, I, C3-6cycloalkyl, C(O)O-lower alkyl, C(O)NH-lower alkyl substituted by halogen, C(O)(morpholine) or is 3,4-dihydronaphthalen-2-yl optionally substituted by lower alkyl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzofuran-6-yl, 1-methyl-2,3-dihydro-1H-indolin-5-yl, 1-methylindolin-5-yl, tetrahydropyran-4-yl, 3,6-dihydro-2H-pyran-4-yl, 2-isopropyl-1,2,3-tetrahydroisoquinolin-5-yl, 2,3-dihydro- dimethyl[1,4]dioxin-6-yl, benzo[1,3]-dioxol-5-yl, 1,2,3,4-tetrahydroisoquinolin-7-yl optionally substituted by lower alkyl, cyclohexenyl, morpholinyl, 4-methylpiperazinyl, naphthalen-1-yl, naphtalen-2-yl, or represents (CHR)n-phenyl optionally substituted by one to five substituents R4, where R4 is F, Cl, CN, CH2-CN, lower alkyl, hydroxy, lower alkyl, substituted hydroxy, lower alkoxy, (CH2)1.2-lower alkoxy, S-lower alkyl, (CH2)1.2-S-lower alkyl, -CH2)1.2-S (O)2-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkylamino, -S(O)2-piperidinyl, lower alkyl substituted by halogen, -N=N-phenyl, di-lower alkylamino, (CH2)1.2-di-lower alkylamino, (CH2)2-NH-lower alkyl, NHC(O)-lower alkyl, lower alkoxy substituted by halogen, CH(CH3) C(O)O-lower alkyl, O-phenyl, O-benzyl, phenyl, optionally substituted CF3, SF5, benzyl, C(O)-lower alkyl, C(O)-phenyl, C(O)-morpholinyl, C(O)-4-methylpiperazinyl, C(O)-di-oxothiomorpholinyl, C(O)-piperidinyl, optionally substituted by F, C(O)-NH-(CH2)2-morpholinyl, C(O)-NR-(CH2)2-NR2, C(O)-N-di-lower alkyl, CH2-O-(CH2)2-4-methylpiperazinyl, CH2-O-(CH2)2-di-alkylamino, CH2-O-(CH2)2-pyrrolidinyl, CH2-O-(CH2)2-morpholinyl, CH2-O-(CH2)2-piperidinyl optionally substituted by lower alkyl substituted by halogen or lower alkyl, (CH2)3,4-pyrrolidinyl, (CH2)2,3-di-lower alkylamino, morpholinyl, CH2-morpholinyl, CH2-piperazine substituted by lower alkyl, -S(O)2-piperazine substituted by lower alkyl, CH2-O-C(O)-piperazine substituted by lower alkyl, pyrazolyl or (CH2)1,2-lower alkoxy; R is hydrogen, lower alkyl or hydroxyl; n is 0, 1, 2, or 3; or R2 is C(O)-phenyl optionally substituted by lower alkyl; or is -O-phenyl optionally substituted by F; or is CH=CH-phenyl optionally substituted by lower alkyl; or is C≡C-phenyl; or R2 is a heteroaryl selected from the group consisting of pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl, isothiazolyl, thiophenyl, 1-thia-3,4-diazolyl, imidazo[1,2-a]pyridinyl, indazolyl, quinolinyl or isoquinolinyl, and the said groups are optionally substituted by R5, where R5 is halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, hydroxy, (CH2)1.2-lower alkoxy, CH2-di-lower alkylamino, di-lower alkylamino, morpholinyl, piperazinyl, pyrrolidin-1-yl, C(O)-piperidinyl, C(O)-4-methylpiperazinyl, phenyl optionally substituted by halogen, pyridinyl, S(O)2N(CH3)2, C(O)O-lower alkyl, NHC(O)-lower alkyl, or is C(O)-heteroaryl selected from pyridinyl and thiophenyl, where heteroaryl groups are optionally substituted by lower alkyl, n is 0, 1, 2 or 3; R3 is hydrogen, methyl, Br, F, Cl, CF3, nitro, amino, cyano, NHC(O)-phenyl, or is 1-methyl-1,2,3,6-tetrahydropyridinyl, or is pyridinyl optionally substituted by methyl or morpholinyl, or is phenyl optionally substituted by methyl , SO2CH3, CF3, CN, F or C(O)N (di-lower alkyl).EFFECT: compounds can be used to treat Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.16 cl, 2 tbl, 256 ex
ethod for obtaining of 1-r-indole-3-ylsulfanylacetates of (2-hydroxyethyl)ammonium // 2642778
FIELD: pharmacology.SUBSTANCE: invention relates to a method for the preparation of indole-1-H-, 1-methyl-, 1-benzylindole-3-ylsulfanylacetate of (2-hydroxyethyl)ammonium heterocyclic compounds that have a broad spectrum of action, for example, selective erythropoiesis and immunomodulators with a minimum potential for undesirable effects on various body systems, and can be used to prevent and treat immune-dependent lesions that occur with anaemia, cancer and inflammatory diseases, complications with organs and bone marrow transplantation, protection against cardiogenic shock, stresses, etc. The method consists in the reaction of 1-R-indole-3-ylsulfanyl acetic acids with (2-hydroxyethyl)amines - triethanolamine, methyldiethanolamine, dimethylethanolamine without solvent upon heating to 60-65°C for 0.5-1 hour, with washing of the resulting salt with ether. The yield is 92-99%. The initial 1-R-indole-3-ylsulfanyl acetic acids (compounds 2) are obtained for this reaction from 1-H- or 1-methyl-or 1-benzylindole with thiourea, bromine, potassium bromide, taken in the molar ratios of 1:2:1:1, respectively, in a water medium at a temperature of 30-40°C for 3 h in inert gas, with subsequent processing of the reaction mass by an aqueous solution of sodium hydroxide, then an aqueous solution of monochloroacetic acid taken in the molar ratios of indole, sodium hydroxide, acid 1:(4-5):(1-1.2), heating of the reaction mixture at 90-100°C for 3 h at a pH of 9-10 with subsequent acidification with hydrochloric acid until pH=1 with a yield of 92-95%. Purity is 98.7-99.7. Replacement of scarce and expensive iodine and potassium iodide in alcohol solution with a more accessible aqueous solution of bromine and sodium bromide, excluding toxic hydrazine hydrate and toxic solvent (alcohol) from the process leads to a decrease in product cost and an increase in environmental fire safety, since the reaction is carried out in an aquatic environment. , R=H, CH3, CH2C6H5; R1, R2=H, CH3, CH2CH2OH; n=1-3.EFFECT: increased efficiency of compounds application.2 cl, 2 dwg, 8 ex
2-aminopyrasine derivatives as csf-1r kinase inhibitors // 2642777
FIELD: pharmacology.SUBSTANCE: invention relates to a compound that is an amino acid or ester of an amino acid of formula , or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against CSF-1R kinase. In formula (I), ring A is a phenyl group; R1 and R2 independently represent a hydrogen atom, a halogen atom or an unsubstituted C1-4 alkyl; n is 1; X is NH; V is -N=, W is -C(Z)=; Z represents a hydrogen atom, a fluorine atom, a chlorine atom or unsubstituted C1-3 alkyl; ring B is a 1,4-phenylene, 1,3-phenylene or pyridinyl group; [Linker] is a -(CH2)m-X1-(Alk1)x-Y1 group, where m is 0, 1, 2 or 3; x is 0 or 1; Alk1 is an unsubstituted C1-3 alkylene group; X1 and Y1 independently represent a bond, -O-, -S-, -NR7th-, -C(=O) - or -C(=O)NR5-, where R5 is a hydrogen atom or C1-4 alkyl and R7 is a hydrogen atom, unsubstituted C1-4 alkyl or -C(=O)CH3; R is a group of formula or , in which R8 is a -COOH group or an ester group of the formula -(C=O)OR14, where R14 is R15R16R17C-, where any R15 represents a hydrogen atom or C1-3alkyl-(Z1)a-[(C1-C3)alkyl]b-, where a and b are independently 0 or 1, Z1 is -O-, -S- or -NH-, R16 and R17 independently represent a hydrogen atom or C1-3 alkyl- or R15 and R16, taken together with the carbon atom to which they are attached, form a 3-7-membered cycloalkyl ring; and R17 represents a hydrogen atom; where (i) R9 and R10 are side chains of natural amino acids, (ii) one of R9 and R10 represents a hydrogen atom or unsubstituted C1-4 alkyl, and the other is an unsubstituted C1-6 alkyl group or C1-6 alkyl group substituted by a C1-4 alkoxy group, or (iii) R9 and R10, taken together with the carbon atom to which they are attached, form a saturated spiro-cyclobutyl ring; R11 represents a hydrogen atom or an unsubstituted C1-2alkyl group; ring D is a 5- to 7-membered saturated heterocyclyl group with at least one nitrogen atom in the ring. The invention also relates to a pharmaceutical composition, a method of treatment or prevention of diseases or disorders mediated by CSF-1R kinase, as well as application of the said compounds for preparation of a medicament useful for treatment of such diseases.EFFECT: increased application efficiency.18 cl, 59 ex
ethod of producing trans-1,4,5,8-tetranitroso-1,4,5,8-tetraazadecalin // 2642470
FIELD: chemistry.SUBSTANCE: invention relates to a method of producing trans-1,4,5,8-tetranitroso-1,4,5,8-tetraazadecalin by the condensation of glyoxal with ethylenediamine in the presence of sodium nitrite and acetic acid with subsequent dosage of the reaction mixture in dilute mineral acid, in which 30-40% sulfuric acid is used as mineral acid, and p-toluensulfonate is introduced into a mixture of glyoxal, ethylene diamine, sodium nitrite, acetic acid.EFFECT: development of highly effective environmentally safe way of obtaining a compound.2 cl, 1 tbl, 8 ex
ethod of producing nitronylnitroxyl radical 2-(5-methyl-1n-imidazole-4-yl)-4,5-bis(spiropentane)-4,5-dihydro-1n-imidazol-3-oxid-1-oxyl // 2642468
FIELD: chemistry.SUBSTANCE: invention relates to a method of producing nitronylnitroxyl radical 2-(5-methyl-1N-imidazole-4-yl)-4.5-bis(spiropentane)-4.5-dihydro-1N-imidazole-3-oxide-1-oxyl, which consists in interacting 1.1'-dihydroxylation-bicyclopentyl produced by the neutralisation of the alkaline agent to the corresponding sulfate salt of 1,1'-dihydroxylation-bicyclopentyl, 4-methylimidazole-5-carbaldehydes in an aqueous solution when heated, and by the oxidation of the resulting product with sodium periodate, with the subsequent release of the specified nitronylnitroxide radical. .EFFECT: application as an effective and low-toxic contrast agent for MR-tomography of living organisms.2 ex
ultifunctional quinoline derivatives as antineurodegenerative agents // 2642466
FIELD: chemistry.SUBSTANCE: invention relates to a hydroxy-derived quinoline of the formula (I) or to a pharmaceutically acceptable salt thereof, (I) wherein R1 is hydrogen, (C1-C3)alkyl, (C1)alkylene(C3)cycloalkyl, (C1)haloalkyl or (C1)alkylene(C6)aryl; R2 is hydrogen or halogen; R3 is hydrogen, halogen, (C1)alkyl or (C1)alkoxy; R4 is hydrogen, halogen, (C1)alkyl, (C1)alkoxy or (C1)haloalkyl; R5 and R6 are hydrogen; and R7 is (C9-C15)alkanol, (C1)alkylenepiperazinyl(C1-C2)alkanol, (C1-C8)alkylenepiperazinyl (C1-C2)alkyl, (C10-C13)alkylene OCOCH3, (C1)alkylene(C1)alkylamino(C3)alkynyl, (C1)alkyleneamino(C8)alkanol or (C1)alkyleneamino(C6)alkanol(C1)alkylene(8-methoxyquinolin-2-yl); or (II), where R1, R2, R3, R4 and R6 each is as described in (I) above; R5 is (C11-C12)alkanol, and R7 is hydrogen. The invention also relates to a pharmaceutical composition based on the formula (I) compounds, a method for treatment of Alzheimer's disease, traumatic brain injury and/or damage to the spinal cord and a method for improvement of the ability of learning and/or memory in a patient suffering from Alzheimer's disease, based on the formula (I) compound.EFFECT: new hydroxy derivatives of quinoline have been obtained that have useful biological properties.13 cl, 13 dwg, 9 ex
Cyclopropane carboxylate ethers of purine analogues // 2642463
FIELD: pharmacology.SUBSTANCE: invention relates to new cyclopropane carboxylate esters of purine analogues of the formula (T) or pharmaceutically acceptable salts thereof, which can be used for treatment of herpesvirus infections. Herpesvirus infection is an infection caused by the herpes simplex virus, infection of herpes zoster, or cytomegalovirus infection. In the compound of the formula (T) each Rx and Rz is independently hydrogen or (C1-C6)alkyl, or Rx is hydrogen and Rz is (C1-C6)alkyl, or Rx is (C1-C6)alkyl and Rz is hydrogen; and Ry is (C1-C6)alkyl, halo (C1-C6)alkyl, C6aryl, haloC6aryl or (C4-C5)heteroaryl with one heteroatom selected from nitrogen and oxygen in the ring.EFFECT: increased efficiency of compounds application.7 cl, 5 dwg, 3 tbl, 16 ex
ethod for obtaining of n-aryl-substituted 3h-imidazo[4,5-b] pyridines // 2642456
FIELD: pharmacology.SUBSTANCE: invention relates to a method of obtaining N-aryl-substituted 3H-imidazo[4,5-b] pyridines, formula shown below, where R=H, OCH3, CH3, Cl, involving nucleophilic substitution of the chlorine atom in 2-chloro-3-nitro-6-R-pyridine in a reaction with imidazole, deoxidizing isomerization recycling of N-(3-nitro-6-R-pyrid-2-yl) benzimidazoles. Nucleophilic substitution is carried out in DMF in the presence of K2CO3 for 1 hour at a temperature of 50°C and molar ratio of 2-chloro-3-nitro-6-R-pyridine:benzimidazole:K2CO3=1:1:1.5, deoxidizing isomerization recycling of N-(3-nitro-6-R-pyrid-2-yl)benzimidazoles is performed by SnCl2⋅2H2O at a temperature of 80°C for 20 h in a mixture of isopropanol and 18% hydrochloric acid taken in a volumetric ratio of 1:1, and molar ratio of 1-(3-nitro-6-R-pyridine-2-yl)-1H-benzimidazole : SnCl2⋅2H2O=1:3.5.EFFECT: method is developed for preparation of these derivatives, which can be used as precursors for drugs.8 ex
Urea derivatives and their application as inhibitors of fatty acids connecting protein // 2642454
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula , where R1 and R2 together with the carbon atom to which they are attached form C3-C10-cycloalkyl; R3 is H or C1-C12-alkyl; R4 is H; W is a bond; A is phenyl substituted by R8, R9 and R10; B is phenyl substituted by R11, R12 and R13; R8 R9 R10 are independently selected from H, halogen-C1-C12-alkyl, halogen; R11, R12 and R13 are independently selected from H, halogen; or pharmaceutically acceptable salts thereof. A pharmaceutical composition, application of a compound of formula (I) and a method for treatment and preventingon of type 2 diabetes, atherosclerosis, cancer, chronic renal failure and non-alcoholic steatohepatitis are also provided.EFFECT: formula compound inhibits the activity of FABP4 and FABP5 proteins and can be used to treat and prevent the aforementioned diseases.17 cl, 17 ex

Shell-and-tube heat exchangers in processes of hydrocarbon degradation c3-c5 (versions) // 2642440
FIELD: chemistry.SUBSTANCE: invention relates to the shell-and-tube countercurrent heat exchanger to heat the raw vapours in the processes of dehydrogenation of paraffin hydrocarbons C3-C5 by the heat of contact gas coming from the dehydrogenation reactor comprising a vertical cylindrical casing (1 ), a bundle of the heat exchanging tubes (2) with an upper (4) and a lower (3) tube gratings, a nozzle (5) and a distributing chamber (6) to input the contact gas in the upper part of the tube space (2) of the heat exchanger (11), a collecting chamber (7) and a nozzle (8) to output the chilled contact of gas from the lower part of the tube space, as well as nozzles (9) to input vapours of the raw material in the annular space of the heat exchanger (11), divided into sections by transverse horizontal partitions of the segment type (13), and to output (10) the heated vapours of raw materials from it. The heat exchanger is also characterized by the fact that the heat exchanger (11) contains connections (12) to supply a part of the feed raw material in a liquid form for the heat exchanger (11) into the intertube space of the bundle of the heat exchange tubes (2) and/or into the intertube space of the bundle of the heat exchange tubes (2) divided by sectors (17), which are limited to the upper (4) and lower (3) tube gratings and vertical channels (18) between the sectors (17). A version of a shell-and-tube heat exchanger for cooling the contact gas is also proposed.EFFECT: increase in capacity of dehydrogenation plants of hydrocarbons C3-C5 and reducing the costs in production.22 cl, 6 dwg, 8 ex, 2 tbl
Obtaining of ioforminol - radio-opaque agent // 2642436
FIELD: chemistry.SUBSTANCE: invention refers to a method of obtaining a compound (1) used as a contrast agent for carrying out radiological studies, from the compound (3). In the compound (3), each X individually represents hydrogen, a formyl group (-CO-H) or an acetyl group (-CO-CH3). The method includes a base-activated in situ hydrolysis of the protecting groups (-OX) of the compound (3), comprising the following successive steps: i) suspending the compound (3) in water; ii) adjusting the pH of the solution obtained in step i) to a value between 10.0 and 12.5.EFFECT: method makes it possible to shorten the reaction time and increase the yield of the compound.6 cl, 1 ex

7-(4-methoxyphenyl)-5-phenyl-4,5-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine as activator of glucokinase and inhibitor of dipeptidyl peptidase of type 4 and method of its production // 2642432
FIELD: chemistry.SUBSTANCE: invention relates to 7-(4-methoxyphenyl)-5-phenyl-4,5-dihydro-[1,2,4]triazolo [1,5-a]pyrimidine as an activator of glucokinase and an inhibitor of dipeptidyl peptidase of type 4: . The invention also relates to the method of its production.EFFECT: new compound is produced that can be used as an activator of glucokinase and an inhibitor of dipeptidyl peptidase of type 4.2 cl, 3 dwg, 3 ex
Amide derivatives as grp119 agonists // 2642429
FIELD: pharmacology.SUBSTANCE: invention relates to an amide derivative of the following formula 1, its stereoisomers or its pharmaceutically acceptable salts of formula 1, wherein X1, X2, X3, X4, X5, X6, X7 and X8 each independently is C or N; R1 is -F or -C1-3-perfluorinated alkyl; R2 and R3 each is independently selected from the group consisting of halogen, -C1-5-alkyl and C3-6-cycloalkyl, wherein -C1-5-alkyl and C3-6cycloalkyl independently of one another may be unsubstituted or substituted by halogen, -CN, -OC1-5-alkyl or-C1-5-alkyl, or R2 and R3 together with the carbon atom to which they are attached, can form C3-6-cycloalkyl, where C3-6cycloalkyl may be unsubstituted or substituted by halogen, -OC1-5-alkyl or -C1-5-alkyl; R4 and R5 each independently is H, halogen or -C1-5-alkyl; R6 and R7 each independently is H, halogen, -C1-5-alkyl or -CN; R8 means methyl; R9 means H, halogen or OH; and m is 1 or 2. The invention also relates to individual compounds and to a pharmaceutical composition.EFFECT: new compounds of formula 1 are obtained that have the properties of GPR119 agonists, which can be used in diabetes mellitus treatment.7 cl, 15 tbl
N-aryl-4-(5-nitrofuran-2-yl)-pyrimidine-5-amines with antibacterial activity and method for their obtaining // 2642428
FIELD: pharmacology.SUBSTANCE: invention relates to new N-aryl-4-(5-nitrofuran-2-yl)-pyrimidine-5-amines of general formula I , where a: R1=R2=R3=H; b: R2=CH3, R1=R3=H; c: R2= OCH3, R1=R3=H; d: R1=R2=R3=OCH3 and a method for their preparation, in which 5-bromo-4-(5-nitrofuran-2-yl)pyrimidine (6) is mixed with the corresponding arylamine taken in 1.5 times excess, palladium (II) acetate and 1,1'-bis (diphenylphosphino)ferracene taken in catalytic amounts and potassium phosphate taken in 2.5-fold excess, the resulting mixture is dissolved in degassed 1,4-dioxane and heated at 85°C with vigorous stirring for at least 15 hours, followed by solvent distillation on a rotary evaporator under reduced pressure, and the resulting residue is subjected to chromatographic separation on a silica gel column with a ratio of ethyl acetate: hexane components of 1:3 in the eluent.EFFECT: highly effective method is proposed for the preparation of a compound that has a broad spectrum of antibacterial activity against coccal infections caused by gonococci or staphylococcus aureus, as well as purulent inflammatory infectious diseases of skin and mucous membranes caused by staphylococci and streptococci.2 cl, 1 tbl, 4 ex
1-ethyl-6-fluoro-4-oxo-7-(8-ethoxy-2-oxo-2h-chromen-3-yl)-1,4-dihydroquinoline-3-carboxylic acid with anti-tubercular activity // 2642426
FIELD: pharmacology.SUBSTANCE: invention relates to a fluoroquinolone carboxylic acid derivative, namely 1-ethyl-6-fluoro-4-oxo-7-(8-ethoxy-2-oxo-2H-chromen-3-yl)-1,4-dihydroquinoline-3 carboxylic acid of formula .EFFECT: high antitubercular activity, including that with respect to strains of mycobacteria with multiple drug resistance.2 tbl, 1 ex
ethod of producing 6-ethoxycarbonyl-7- (thien-2-yl) -5-methyl-4,7-dihydro-1,2,4-triazolo [1,5-a]pyrimidine that has high tuberculostatic activity // 2642420
FIELD: chemistry.SUBSTANCE: invention relates to a method of producing 6-ethoxycarbonyl-7-(thien-2-yl)-5-methyl-4,7-dihydro-1,2,4-triazolo[1,5-a]pyrimidine having tuberculostatic activity of the formula , which consists in interaction of 2-thiophenaldehyde, acetoacetic ester and 3-amino-1,2,4-triazole by heating in a solvent, where water is used as the solvent, with a molar ratio water: 2-thiophenaldehyde: acetoacetic ester: 3-amino-1,2,4-triazole is 55:1:1:1.EFFECT: new simple technological method of obtaining a compound that does not require special equipment and acids and large volumes of organic solvents is developed.3 ex

Antigen-binding molecule, able to multiplely contact with plurality of antigenic molecules // 2642318
FIELD: biotechnology.SUBSTANCE: molecule containing a human antigen-binding domain and a FcRn-binding domain with antigen-binding activity different in two different conditions of calcium concentration and lower in conditions of low calcium concentrations compared to the conditions of high calcium concentration, where the low calcium concentration represents the concentration of ionized calcium of 0.1 to 30 mcm, and the high calcium concentration is ionized calcium concentration of 100 mcm to 10 mm, where the specified antibody contains at least four amino acids selected from the group consisting of amino acids at positions 30, 31, 32, 50 and 92, in accordance with the numbering along the Kabat light chain, with chelant activity against metal. Also, a pharmaceutical composition comprising the antibody is described. The invention can be used to accelerate the capture of the antigen by antigen-binding molecules into cells, increase the number of times of antigen binding by one molecule, accelerate the reduction of antigen concentration in plasma and increase the retention of an antigen-binding molecules in the plasma, as well as antigen-binding molecules.EFFECT: decreased antigen concentration in plasma.5 cl, 56 dwg, 28 tbl, 25 ex

ethods for selective quantitative assessment of a-beta aggregates // 2642314
FIELD: biotechnology.SUBSTANCE: method for quantitative assessment and characterisation of A-beta aggregates is described, comprising the following steps: a) entrainment molecules immobilisation on a substrate, b) application of a test sample and an internal standard to the substrate, c) addition of probes labeled for detection to label A-beta aggregates through specific binding to them, and d) determination of the number and size of labeled A-beta aggregates with spatial resolution in each case compared to the corresponding background, at that step b) can be carried out prior to step c). Also a kit for implementation of the described method, comprising a standard and one or more of the following: a glass substrate coated with a hydrophobic substance; an entrainment molecule; a probe; a substrate with the entrainment molecule; solutions; and a buffer, is presented. A method for determination of the efficacy of active substances and/or therapies for Alzheimer's disease treatment is provided, characterized by a) entrainment molecules immobilization on the substrate, b) test sample and internal standard application to the substrate, c) addition of probes labeled for detection, that label A-beta aggregates through specific binding to them, and d) determination of the number and size of labeled A-beta aggregates with spatial resolution in each case compared to the corresponding background. Step b) can be performed prior to step c), e) the results obtained on samples that are samples of a body fluid taken before or at various times after active substances administration and/or therapy are compared with the results obtained for control, which was not treated with the active substance and/or subjected to therapy, and based on the results obtained, active substances and/or therapies are selected, after which a reduction in the amount of A-beta aggregates was observed.EFFECT: invention expands the arsenal of means intended for definition of efficiency of Alzheimer's disease treatment.43 cl, 7 dwg, 3 ex
ethod for production of hydroxylated cyclopentapyrimidine compounds and their salts // 2642311
FIELD: biotechnology.SUBSTANCE: method for production of a formula III compound or a salt thereof, . The compound of formula or its salt is brought into contact with ketoreductase or alcohol dehydrogenase enzyme.EFFECT: invention allows stereoselective reduction of a compound of formula II or a salt thereof to a compound of formula III or a salt thereof that is suitable for further synthesis of ACT protein kinase activity inhibitors.15 cl, 3 dwg, 2 tbl, 6 ex

Fusion serpine polypeptides and methods for their application // 2642310
FIELD: biotechnology.SUBSTANCE: invention relates to the field of fusion proteins for serine proteases inhibition, and can be used in medicine. Fusion proteins having at least one human alpha-1 antitrypsin (AAT) polypeptide operably linked to an immunoglobulin Fc polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:6 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.18 cl, 4 dwg, 4 ex

Cancer treatment using targeted antibodies in vivo // 2642305
FIELD: biotechnology.SUBSTANCE: antibody binding to claudine 6 (CLDN6) and inhibiting tumor growth in vivo is claimed. The antibody can be used as part of a pharmaceutical composition, in a method for treatment of tumor related to cells expressing CLDN6. The invention also relates to hybridomas producing antibodies to CLDN6 deposited under the accession numbers DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), DSM ACC3057 (GT512muMAB 5F2D2).EFFECT: invention effectively inhibits the growth of CLDN6-positive germ cell tumors, improves survival and prolongs life of patients with tumors.17 cl, 18 dwg, 5 ex
Combined administration of gdf traps and erythropoetin receptor activators for increasing content of erythrocytes // 2642302
FIELD: biotechnology.SUBSTANCE: method of treatment comprises of administration to the patient of an isolated polypeptide including the amino acid sequence of SEQ ID NO: 28.EFFECT: invention makes it possible to effectively increase the contents of erythrocytes in patients.17 cl, 22 dwg, 19 ex

Immunotherapeutic compositions on the basis of yeast-muc1 and methods of their use // 2642300
FIELD: biotechnology.SUBSTANCE: fusion protein is produced which contains the MUC1 antigen having an amino acid sequence that is at least 85% identical to the sequence of SEQ ID NO: 25 or at least 95% identical to the positions 92-566 of the sequence of SEQ ID NO: 25, and where MUC1 antigen contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acids L184, Y232, L233, V240, V241, L242, Y483, V497, L335, F536 and Y551.EFFECT: invention allows to effectively treat Mucin-1-expressing carcinomas, and also to prevent their metastatic progression.14 cl, 3 dwg, 5 tbl, 10 ex

P53 peptidomimetic macrocycles // 2642299
FIELD: biotechnology.SUBSTANCE: stable cross-linked p53 peptidomimetic macrocycle, a method for its preparation and its use are proposed. The p53 peptidomimetic macrocycle has a structure represented in the formula, and interferes with binding of p53 to MDM2 and/or p53 to MDMX. The P53 peptidomimetic macrocycle can be used to prepare pharmaceutical compositions for treatment of cancer characterized by undesirably low or low p53 activity and/or for the treatment of cancer characterized by undesirably high levels of MDM2 or MDMX activity.EFFECT: proposed cross-linked p53 macrocycle has cell permeability that is at least twice as high as that of the corresponding macrocycle without cross-links.50 cl, 7 dwg, 9 tbl, 22 ex

Analysis of identification of antibodies specific to therapeutic antibodies against ige, and their application in anaphylaxis // 2642295
FIELD: biotechnology.SUBSTANCE: methods for detection of a human IgE isotype antibody against omalizumab are provided. Sets, methods for identification of a patient at risk of an anaphylactic reaction to omalizumab, and a method for treatment of a patient with an IgE-mediated disorder are also contemplated.EFFECT: invention allows timely detection of allergic reactions to omalizumab and can be used in therapy and prevention of anaphylaxis.52 cl, 27 dwg, 7 tbl, 7 ex

Hpv chimeric particle // 2642287
FIELD: biotechnology.SUBSTANCE: chimeric virus-like particle (VLP) of human papilloma virus (HPV), and method for its production and extraction, methods for prevention or treatment of HPV infection or cervical cancer, and for induction of an immune response in the patient, including the administration of proposed HPV VLP, as well as the application of the proposed HPV VLP in these methods and in production of pharmaceuticals to implement these methods, are proposed. The proposed chimeric HPV VLPS has a diameter of about 30 nm and contains a chimeric polypeptide HPV 16 L1/L2, which consists of a polypeptide HPV 16 L1, in which the peptide HPV 16 L2 from the amino acid residue 414 is inserted. The peptide contains from 13 to 26 amino acids. The amino acids of the inserted HPV 16 L2 peptide replace the corresponding amino acids of the HPV 16 L1 polypeptide. A method is also provided for the production of said HPV VLP in a plant in which successful assembly of small chimeric HPV VLPs, having a diameter of 30 nm, takes place.EFFECT: proposed group of inventions can be used in medicine for the prevention or treatment of HPV infection or in antitumor therapy for cervical cancer.28 cl, 32 dwg, 11 tbl, 3 ex
ethod for production of target antibody with modulated galactosylation (versions) and method for modulation of target antibody galactosylation (versions) by culture medium optimisation // 2642285
FIELD: biotechnology.SUBSTANCE: methods for production of a target antibody with modulated galactosylation (versions), methods for modulation of the target antibody galactosylation (versions) by culture medium optimisation are provided. The methods provide increasing the osmolality of the solution for culturing animal cells and/or asparagine addition to the solution at a certain point in time of the cell culturing process.EFFECT: obtaining of the desired antibody population.19 cl, 3 dwg, 8 tbl, 3 ex
ethod for conserving and stabilizing proteins // 2642277
FIELD: biotechnology.SUBSTANCE: invention can be used for commercial development of the compositions used in the sanitary, pharmaceutical and cosmetic products, in particular cell growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (bFGF). In accordance with the present invention, the proteins are placed in an anhydrous medium formed by oil components having hydrophilic properties and interacting with proteins while conserving their native conformation.EFFECT: increasing the stability of protein dispersion.1 cl

Thrombin-binding molecules of antibodies and their application // 2642276
FIELD: pharmacology.SUBSTANCE: isolated antibody molecule, specifically binding to the thrombin exosite area 1, and an antigen-binding fragment of said antibody, are provided. The use of the antibody molecule in the manufacture of medicaments is considered. A pharmaceutical composition is described as well as a method for treating a thrombin-mediated condition.EFFECT: use in the treatment of diseases associated with thrombin.25 cl, 22 dwg, 4 tbl

Composition for hyperlipidemia treatment containing oxyntomodulin derivative // 2642267
FIELD: biotechnology.SUBSTANCE: oxyntomodulin derivative with SEQ ID NO: 24, 25 or 26 fused to the Fc region of the immunoglobulin via a non-peptidyl polymer that covalently binds the oxyntomodulin derivative and the immunoglobulin Fc region is obtained.EFFECT: invention allows to obtain a conjugate of a oxyntomodulin derivative with a high ability to activate the GLP-1 receptor and a glucagon receptor compared to natural oxyntomodulin and to effectively lower the levels of total cholesterol, low density cholesterol and triglycerides in blood that have been elevated due to a high fat diet and to raise high-density cholesterol levels and high-density cholesterol - low-density cholesterol ratios.13 cl, 10 dwg, 3 tbl, 6 ex

Humanized antibodies, which recognize alpha-sinuclein // 2642262
FIELD: biotechnology.SUBSTANCE: antibody is described comprising a mature variable region of the heavy chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 44 and at least 90% identical to the sequence of SEQ ID NO: 44 and a light chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 45, and at least 90% identical to the sequence of SEQ ID NO: 45, where the antibody specifically binds to a human alpha-synuclein. A pharmaceutical composition comprising the described antibody is also described. A method of treating a patient having a disease with Levy bodies or having a risk of developing the disease or a method for detecting Levy bodies in a patient having a disease with Levy bodies or having a risk of developing the disease, comprising appointing to the patient an effective regimen for administering the described antibody, is provided.EFFECT: invention provides antibodies which bind to a human alpha-synuclein and can be used to treat and diagnose a disease with Levy bodies.80 cl, 6 dwg, 5 tbl, 2 ex

Polypeptide for blood sugar level reducing on basis of human glucagon-like peptide-1, recombinant producing strain e. coli and method of obtaining this polypeptide // 2642260
FIELD: biotechnology.SUBSTANCE: recombinant modified human glucagon-like peptide-1 (rmGLP-1), a method for its preparation, and strain E.coli RNCIM B-12555 are proposed. rmGLP-1 has the sequence of SEQ ID NO 1. rmGLP-1 is produced by culturing a recombinant strain E. coli RNCIM B-12555 to prepare the rmGLP-1 peptide precursor, then isolating the resulting precursor, its autocatalytic cleavage and purification of the target polypeptide. The mouse model shows that with subcutaneous or intramuscular administration, rmGLP-1 has indicators of sugar reduction activity and duration of action similar to that of the commercial preparation "Lysxemia" obtained using chemical synthesis and, for a minimum of 3 hours after administration, is able to effectively reduce the level of glucose in blood almost twice as compared with the control.EFFECT: abovementioned strain allows biosynthesis of the precursor rmGLP-1 at 40 percent of the total protein of the cells, which corresponds to the biosynthesis of rmGLP-1 at 13 percent of the total cell protein.3 cl, 3 dwg, 7 ex
Compositions, synthesis and methods for application of phenylcycloalkylmethylamine derivatives // 2642074
FIELD: pharmacology.SUBSTANCE: invention relates to new phenylcycloalkylmethylamine derivatives of structural formula (I), or enantiomers or optically active isomers, or pharmaceutically acceptable salts having affinity for the binding of dopamine (DAT), the carrier of norepinephrine (NET) and the serotonin transporter (SERT). The compounds may find use in treatment and/or prevention of obesity, as well as depression 1. In the structural formula (I) ,n is 1; SP is a spacer, wherein the said spacer is C4 alkylene; X is O or S; R1 and R2 are independently H, C1-6 alkyl, C1-6 alkoxy, halogen; R3 is C1-6 alkyl; R4 is H or C1-6 alkyl; R5 is C1-6 alkyl; and * represents a carbon atom that can be optically active.EFFECT: improved composition properties.12 cl, 1 tbl, 86 ex

Aqueous alkanolamine absorbing composition containing pyperazin for improved removal of hydrogen sulphide from gaseous mixtures, and method of its use // 2642071
FIELD: chemistry.SUBSTANCE: aqueous solution of alkanolamine to remove acid gases, including hydrogen sulfide from gaseous mixtures containing hydrogen sulfide, includes: (i) from 20 up to 50 weight percentage of 3-(dimethylamine)-1,2-propane diol or 3-(diethylamine)-1,2-propane diol, and (ii) from 2 to 10 weight percentage of piperazine. Weight percentage is taken based on the total weight of the aqueous solution of alkanolamine and wherein the said aqueous solution of alkanolamine does not contain orthophosphoric acid, phosphoric acid, hydrochloric acid, sulfuric acid, sulfurous acid, nitric acid, pyrophosphoric acid, tellurium acid, acetic acid, formic acid, adipic acid, benzoic acid, n-butane acid, monochloroacetic acid, citric acid, glutaric acid, lactic acid, malonic acid, oxalic acid, o-phthalic acid, succinic acid, o-toluic acid. A method for removing acid gases from a gas mixture is also disclosed.EFFECT: claimed aqueous amine solution provides removal of hydrogen sulfide and carbon dioxide at a lower consumption of the absorbent.6 cl, 1 tbl, 2 dwg

New ester compound of alicyclic dicarboxylic acid and method of its production // 2642069
FIELD: chemistry.SUBSTANCE: invention relates to a new ester compound of an alicyclic dicarboxylic acid represented by the formula (1), wherein each R independently represents an alkyl group having 1 to 4 carbon atoms. The invention also relates to a method of producing esters of alicyclic dicarboxylic acid, including stages of the interaction of 4-isopropenyl-1-methyl-1-cyclohexene represented by the following formula (3), with carbon monoxide in the presence of hydrogen fluoride with the formation of fluoride alicyclic dicarboxylic acid represented by the following formula (2); and the interaction of the obtained fluoride alicyclic dicarboxylic acid represented by the following formula (2), alcohol with the formation of ester compound of alicyclic dicarboxylic acid represented by the formula (1).EFFECT: resulting new ester compound can be used, for example, as a starting material for polyester resins.3 cl, 14 dwg, 3 ex
N-pyperonyl derivatives of daunorubicine, with antiprofliferative properties // 2642068
FIELD: pharmacology.SUBSTANCE: invention relates to the N-piperonyl derivatives of daunorubicine, which can be used in medicine, of general formula I where R=H, OCH3.EFFECT: new daunorubicine derivatives with antiproliferative properties and relatively low acute toxicity are proposed for cancer treatment, including non-small cell lung cancer, rhabdomyosarcoma, bowel carcinoma, breast adenocarcinoma.2 cl, 1 tbl, 2 ex
Spiro-fused piperidine derivatives for application as inhibitors of external medullar layer potassium channel // 2642066
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula I .EFFECT: new compounds of formula I are obtained which are inhibitors of the ROMK channel and which can be used in hypertension treatment.11 cl, 5 tbl, 85 ex
Derivatives of 1-(4,5-dihydroimidazole)-isochromane or 1-(4,5-dihydro)-isothiochromane, which are useful as agonists of alpha2 adrenoreceptors // 2642065
FIELD: chemistry.SUBSTANCE: invention relates to a compound of the formula or a pharmaceutically acceptable salt thereof, wherein X is O or S; R1 is hydroxyhalogen, (C1-C6)alkyl, halogen(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, cyclo(C3-C6)alkyl, (C1-C6)alkoxy, halogen(C1-C6)alkoxy, hydroxy(C1-C6)alkyl, cyano, (R6)2N-(C=O)-, (C1-C6)alkyl-S-, or furanyl; R2 is H or (C1-C6)alkyl; R3 is H, (C1-C6)alkyl, halogen(C1-C6)alkyl or (C1-C6)alkoxy(C1-C6)alkyl; R4 is H or (C1-C2)alkyl; R5 is H, hydroxy, halogen, (C1-C6)alkyl or (C1-C6)alkoxy; R6 is H; or R1 and R2 form rings together with carbon atoms, to which they are attached, a fused 6- or 7-membered saturated or unsaturated carbocyclic ring. The invention also relates to a pharmaceutical composition based on a compound of formula (I).EFFECT: new isochromane or isothiochromane derivatives, useful as alpha2 adrenoreceptor agonists, have been obtained.10 cl, 1 tbl, 106 ex
Hybrid terpenophenols with isobornyl and 1-phenylethyl or 1-phenylpropyl substituents and their application as agent, possessing anti-radical, antioxidant and membrane-protection activity // 2642062
FIELD: pharmacology.SUBSTANCE: invention relates to new hybrid terpenophenols with isobornyl and 1-phenylethyl or 1-phenylpropyl substituents of formula , (I) R=Me; R1, (II) R=H; R1, (III) R=Me; R1, (IV) R=Me; R2, (V) R=H; R2, (VI) R=H; R2, excluding (I-III), and also to the application of hybrid terpenophenols of formula (I-VI) as an agent, possessing antiradical, antioxidant and membrane-protection activity and low toxicity.EFFECT: increased efficiency of agents.2 cl, 5 tbl, 7 ex
4-amino-3-methoxymethyl-5-phenyl-1h-pyrazole // 2642060
FIELD: pharmacology.SUBSTANCE: invention relates to preparation of new 4-amino-3-methoxymethyl-5-phenyl-1H-pyrazole previously not described. 4-amino-3-methylamide-5-phenyl-1H-pyrazole that has the following equation, derived from cycloaromatization of isonitrosodiketone and restoration of a new, not previously described intermediate - 4-nitroso-3-methylamide-5-phenyl-1H-pyrazole. The resulting target compound shows high antibacterial activity against E. coli (Escherichia coli strain ATCC 25822, sensitive to antibiotics) that allows its use in pharmacology to create antibacterial drugs. .EFFECT: increased efficiency of compounds application.2 ex
Complex compaund of gold-chlorine hydrogen acid with l-lysin, having radiopaque properties, which may be used for diagnostics of early tumor masses, including diagnosis of marek's disease in birds // 2642059
FIELD: veterinary science.SUBSTANCE: invention relates to a complex compound of hydrochloric acid with L-lysine having radiopaque properties.EFFECT: complex compound can be used to diagnose early tumor mases, including to diagnostics of Marek's disease in birds.1 cl, 2 ex
Heterocyclic compounds as pesticides // 2641916
FIELD: chemistry.SUBSTANCE: non-therapeuticuse of heterocyclic compounds of the formula for controlling animal pests, including arthropods, insects, and nematodes.EFFECT: invention allows to realise the specified purpose.18 cl, 5 tbl, 48 ex
3-aminocyclopentancarboxamide derivatives // 2641913
FIELD: chemistry.SUBSTANCE: invention relates to the individual compounds selected from the group: 4-(1,3-benzoxazole-2-yl)]-N-[(1R,3S)-3-(ethylcarbamate)cyclopentyl]-N-methylbenzamide, N-((1R,3S)-3-ethylcarbamoylcyclopentyl)-N-methyl-4-(1-methyl-1H-benzoimidazol-2-yl)-benzamide, 4-benzothiazol-2-yl-N-((1R,3S)-3-ethylcarbamoylcyclopentyl)-N-methylbenzamide, ((1R,3S)-3-ethylcarbamoylcyclopentyl)-methylamide4'-[(R)-(tetrahydrofuran-3-yl)oxy]-biphenyl-4-carbon acid, 4-benzoxazole-2-yl-N-((1R,3S)-3-isopropylcyclopentadienyl)-N-methylbenzamide, and other compounds that are specified in the claims. The invention also relates to medicinal means having an inhibiting activity against fatty acid synthase (FAS) containing therapeutically effective amount of the compound of the invention.EFFECT: new compounds are obtained that have an inhibiting activity against the synthesis of fatty acids.2 cl, 2 tbl, 12 ex
New semi-synthetic eremomycine derivative and its application // 2641912
FIELD: pharmacology.SUBSTANCE: invention relates to a new semi-synthetic derivative of glycopeptide eremomycine antibiotic, which is eremomycine tetramethylenimide of formula , and its pharmaceutically acceptable salts. A method for production of eremomycine tetramethylenimide of formula 2, its pharmaceutical compositions and their use for treatment of mammalian infections caused by gram-positive bacteria, including insensitive or low-sensitive to other antibiotics.EFFECT: compound efficiency increase.6 cl, 4 tbl, 6 ex

Urea solution concentration in method of urea synthesis // 2641911
FIELD: chemistry.SUBSTANCE: urea-containing solution (13) is produced in the section (10) of synthesis, the solution is purified in the section (14) of extraction, and an aqueous solution (15) containing mostly urea and water, which is produced from the above-mentioned section of the extraction is subjected to the concentration process. Herewith the concentration process includes a separation step through an elective membrane.EFFECT: improvement of the current urea production process.9 cl, 1 dwg
 
2550821.
Up!